Latest Clinical News

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (02-11-2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Year in Review: Myeloproliferative Neoplasms (02-10-2016)

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to... Continue Reading

Gastric Cancer Risk Factors You Need to Know (02-8-2016)

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes it very important for people to know their risk... Continue Reading

Halaven Approved for Liposarcoma (02-4-2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading

Colorectal Cancer: Year in Review (02-3-2016)

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has been done with combination therapies and protocols... Continue Reading

Prostate Cancer: Year in Review (02-2-2016)

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the research devoted to best standard of treatment for... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (01-28-2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Combo Therapy of Kyrpolis plus Dexamethasone Approved for Recurrent Multiple Myeloma (01-26-2016)

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (01-25-2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (01-21-2016)

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium... Continue Reading

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer (01-20-2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These... Continue Reading

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (01-19-2016)

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings... Continue Reading

Next Page »